American College of Clinical Pharmacy
      Search      Cart
         

IDSAP 2024 Book 2 Infections in Special Populations


Member Price:
$80.00
Nonmember Price:
$120.00
ASHP members, please call (913)492-3311 to receive multi-book discounts at the member rate. Your ASHP membership number and expiration date are required.

Infectious Diseases Pharmacists are essential in preventing and treating a wide range of infections across diverse patient populations. Infections in Special Populations, the latest release from the Infectious Diseases Self-Assessment Program (IDSAP), provides invaluable resources and practical strategies for effectively preventing and managing infections in pediatric individuals, individuals with central lines, and at-risk youth.

Faculty Panel Chair Jason Child, Pharm.D., BCIDP
Child

The target audience for Infections in Special Populations is board-certified infectious diseases pharmacists who provide care for individuals with or at risk for infectious diseases. Infections in Special Populations contains five learning modules with a total available 23.5 continuing pharmacy education (CPE) credits. Book content was developed under the leadership of Faculty Panel Chair Jason Child, Pharm.D., BCIDP.

 

The first module offers updates on perinatal and neonatal infections and current treatment options. It also explores the unique challenges of managing HIV in select populations, providing practical considerations for clinicians. The second module explores the intricate interplay between innate and acquired immunodeficiencies and their impact on susceptibility to infections. It explores the risk of infections in patients requiring central venous catheters, offering insights into preventive strategies and management considerations. The third module focuses on outpatient antimicrobial therapy and the complexities of antimicrobial management and stability. Pediatric MSK infections with treatment options are also a focus in the third module. The fourth module focuses on updates to the STI treatment guidelines and alternatives in special populations. It includes the updated diagnosis and treatment guidelines for UTI and asymptomatic bacteria. The final module consists of two case series that provide appropriate diagnosis and treatment for pediatric appendicitis and pneumonia. Overall, this resource offers valuable insights into the diagnosis, treatment, and prevention of infections across diverse patient populations with immune deficiencies.

Each IDSAP release has continuing education activities that cover the most recent published data (past 3-5 years) on a specific therapeutic area or patient-care problem. This content is provided as an electronic book (interactive PDF) with high-level updates designed, as appropriate to the topic, in three formats:

  • Traditional review-style chapters
  • Case series (major sections of learning content bookended by a sample case and its explained answer)
  • Recorded webcast (PowerPoint presentation; includes PDF of
Release Date: November 15, 2024
BCIDP Deadline: May 15, 2025
ACPE Deadline: November 15, 2027

ISBN: 978-1-952291-98-2
Publication Year: 2024
Format: PDF and ePub
Number of Pages: 200

Contents

IDSAP 2024 Book 2: Infections in Special Populations Module I

IDSAP 2024 Book 2: Infections in Special Populations Module II

IDSAP 2024 Book 2: Infections in Special Populations Module III

IDSAP 2024 Book 2: Infections in Special Populations Module IV

IDSAP 2024 Book 2: Infections in Special Populations Module V

CPE Credit

The American College of Clinical Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.

The American College of Clinical Pharmacy and the American Society of Health-System Pharmacists are approved by BPS as a provider for the recertification of BCIDP.

BPS is an autonomous division of the American Pharmacists Association. To maintain its strict, independent standards for certification, BPS does NOT endorse or provide review information, preparatory courses, or study guides for board certification examinations. BPS, through its specialty councils, is responsible for specialty examination content, administration, scoring, and all other aspects of its certification programs. BPS is totally separate and distinct from ACCP. For information about BPS specialty recertification the BPS recertification process, go to: www.bpsweb.org/

To receive recertification credit, posttests must be submitted prior to the recertification posttest deadline (see above). Only completed tests are eligible for credit; no partial or incomplete tests will be processed. You may complete one or all available posttests for credit.

The passing point to earn recertification credit is based on an expert analysis of the assessment items in each posttest. Any posttest submitted before the recertification test deadline that meets this passing point will earn recertification credits. These credits will be assigned as of the date of test submission and reported within 48 hours to BPS. For statements of recertification credit, visit www.bpsweb.org.

In accordance with BPS guidelines concerning remediation for products launched in 2024 and after, posttests that do not reach the passing point for recertification credit will generate a second-chance test option. This test will automatically appear in the learner’s My Account page and will have assessment items presented in a different order. To qualify for recertification credit, the second-chance test must be submitted before the recertification deadline stated above.

The ACCP Recertification Dashboard is a free online tool that can track recertification credits as they are earned through ACCP and schedule new opportunities for credits from upcoming ACCP professional development programs. Questions regarding the number of hours required for recertification should be directed to BPS at www.bpsweb.org.

Target Audience: The target audience for Infections in Special Populations is boardcertified infectious diseases pharmacists who provide care for individuals with or at risk for infectious diseases.

Contents

IDSAP 2024 Book 2: Infections in Special Populations Module I

Activity Number: 0217-9999-24-230-H02-P
Contact Hour(s): 5.00
Activity Type: Application Based
Learning Objectives

Chapter: Perinatal Infections Learning Objectives  

  1. Assess current screening and prevention strategies for perinatal infections, including prenatal testing, vaccination programs, and interventions during labor and delivery.
  2. Develop a plan for monitoring and criteria for initiating acyclovir in a neonate born to a mother with genital history of herpes simplex virus.
  3. Design a treatment plan for prevention of hepatitis B infection in a newborn based on maternal serology.
  4. Assess medication regimen for a newborn born to a mother with HIV based on maternal risk factors.
  5. Develop a plan for counseling pregnant women about perinatal infections, addressing concerns with safety of medication during pregnancy and breastfeeding. 

 

Chapter: Neonatal Sepsis Learning Objectives

  1. Analyze differences between risk factors and common organisms in early- versus late-onset neonatal sepsis.
  2. Assess patients for neonatal sepsis on the basis of clinical and laboratory values.
  3. Design an approach for evaluation and management of early-onset neonatal sepsis.
  4. Develop recommendations for the management of late-onset neonatal sepsis.
  5. Evaluate current guidelines for the treatment and prevention of neonatal candidiasis. 

IDSAP 2024 Book 2: Infections in Special Populations Module II

Activity Number: 0217-9999-24-231-H02-P
Contact Hour(s): 4.50
Activity Type: Application Based
Learning Objectives

Chapter: Pediatric Viral Infections Learning Objectives

  1. Distinguish the differences between risk stratification and drug therapy recommendations for treatment of COVID-19 in pediatrics from the leading guidelines.
  2. Assess the differences in the various nucleoside and nucleotide analogs.
  3. Delineate the role and place in therapy of remdesivir in pediatrics for the treatment of acute COVID-19.
  4. Assess the differences in palivizumab and nirsevimab-alip in their efficacy, safety, cost, and availability for prevention of respiratory syncytial virus (RSV).
  5. Evaluate the latest data and availability of nirsevimab-alip for prevention of RSV. 

 

Chapter: Catheter-Related Bloodstream Infections Learning Objectives

  1. Analyze risk factors and preventive strategies for catheter-related bloodstream infections (CRBSIs) in patients with various types of intravascular catheters.
  2. Assess patients with CRBSIs for indications for catheter removal and antimicrobial lock therapy.
  3. Develop empiric antimicrobial regimens for patients with CRBSIs on the basis of patientspecific factors.
  4. Design antimicrobial treatment plans for patients with CRBSIs on the basis of causative organism, catheter type, and patient-specific factors.
  5. Distinguish therapy durations for various CRBSIs.

IDSAP 2024 Book 2: Infections in Special Populations Module III

Activity Number: 0217-9999-24-232-H02-P
Contact Hour(s): 5.00
Activity Type: Application Based
Learning Objectives

Chapter: Outpatient Parenteral Antimicrobial Therapy Learning Objectives

  1. Design a plan to ensure compliance with the CDC core elements of antimicrobial stewardship related to outpatient parenteral antimicrobial therapy (OPAT).
  2. Develop patient-specific intravenous versus oral antimicrobial therapy recommendations according to evidence for the diagnosed infection.
  3. Apply this knowledge to determine the optimal antimicrobial on the basis of evidence, narrowest spectrum of activity, and patient-specific factors to be used for OPAT.
  4. Distinguish between various intravenous catheter options to determine the optimal choice for a given patient according to antimicrobial and duration of therapy.
  5. Develop an individualized plan for managing OPAT after initiation. 

 

Chapter: Pediatric Musculoskeletal Infections Learning Objectives

  1. Compare and contrast pediatric and adult musculoskeletal infections.  
  2. Distinguish between the different classifications of osteomyelitis, septic arthritis, and pyomyositis based on pathophysiology and site of infection.
  3. Develop an empiric treatment regimen for a pediatric patient with a musculoskeletal infection, accounting for clinical presentation, diagnosis, risk factors, patient characteristics and the most likely causative pathogens.
  4. Design a pediatric patient–specific treatment plan for musculoskeletal infection using the narrowest spectrum agent possible while achieving appropriate antimicrobial concentrations.
  5. Evaluate the duration of treatment of a musculoskeletal infection based on patient and infection specific factors.  

IDSAP 2024 Book 2: Infections in Special Populations Module IV

Activity Number: 0217-9999-24-233-H02-P
Contact Hour(s): 4.50
Activity Type: Application Based
Learning Objectives

Chapter: Sexually Transmitted Infections Learning Objectives

  1. Evaluate the clinical presentations of different sexually transmitted infections (STIs).
  2. Identify the preferred and alternative treatments for most patients with STIs according to clinical practice guidelines.
  3. Evaluate pharmacotherapy options for the treatment of STIs in special populations, including pregnancy, pediatrics, and those with HIV infection.
  4. Design a pharmacotherapy treatment plan for patients with STIs. 

 

Chapter: Urinary Tract Infections Learning Objectives

  1. Analyze patient risk factors and laboratory data to determine proper UTI classification and treatment duration.
  2. Assess current best practices for preventing catheter-associated UTIs.  
  3. Distinguish clinical presentation of asymptomatic bacteriuria from uncomplicated UTIs in special patient populations.
  4. Develop antimicrobial treatment plans for patients with individual factors related to UTIs.
  5. Evaluate the pharmacologic options for multidrug-resistant uropathogens.

IDSAP 2024 Book 2: Infections in Special Populations Module V

Activity Number: 0217-9999-24-234-H02-P
Contact Hour(s): 4.50
Activity Type: Application Based
Learning Objectives

Case Series: Appendicitis Learning Objectives

  1. Evaluate a patient’s presenting signs, symptoms, and laboratory values to appropriately assign a risk score for appendicitis.
  2. Distinguish between a nonoperative and operative approach for patients with appendicitis on the basis of presentation, appendicitis classification, and other risk factors.
  3. Design an appropriate antibiotic regimen for the management of appendicitis.
  4. Design a discharge plan for a patient requiring continued antibiotic therapy.
  5. Develop a plan to treat complications stemming from primary management of appendicitis.

 

Case Series: Pediatric Pneumonia Learning Objectives

  1. Distinguish the most common causative pathogens for pediatric community-acquired pneumonia (CAP) on the basis of patient age.
  2. Develop antibiotic treatment regimens for pediatric patients with uncomplicated pneumonia while considering local and patient-specific factors.
  3. Design a medication management plan for pediatric patients presenting with complicated pneumonia.
  4. Analyze pediatric vaccination recommendations to aid in the prevention of CAP.

Commercial Support

The American College of Clinical Pharmacy does not solicit or accept external commercial/financial support for its continuing pharmacy education activities. No commercial/financial support has been solicited or accepted for this activity.